Repatha bests Zetia in study, cutting heart attack risk by 20% beyond statins
The results offer doctors evidence on which non-statin cholesterol medicine to choose for patients who need more risk reduction.
Read at STAT →Full coverage · 6 outlets
- STAT · lead
- Harvard HealthBeyond statins: New ways to lower LDL cholesterol
- MSNAmgen's Repatha cuts death risk by 20% in heart study
- YahooAMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE
- InvestorsOne Of Amgen's Biggest Moneymakers Cuts The Risk Of Dying By 20%
- StreetinsiderAMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE